Daiichi Sankyo Files Application for Dysuria Treatment KMD-3213 in China.Tokyo, Jan 8, 2009 - (JCN) - Daiichi Sankyo announced today that subsidiary Daiichi Pharmaceutical (Beijing) Co., Ltd. filed an application for KMD-3213 (generic name: silodosin) to China's State Food and Drug Administration The State Food and Drug Administration (SFDA Simplified Chinese: 国家食品药品监督管理局) is founded on the basis of the State Drug Administration. (SFDA SFDA State Food and Drug Administration (China) SFDA Saudi Food & Drug Authority ). KMD-3213 is a selective alpha 1A-adrenoceptor antagonist developed for treatment of dysuria dysuria /dys·uria/ (dis-u´re-ah) painful or difficult urination.dysu´ric dys·u·ri·a n. Difficult or painful urination. associated with benign prostatic hyperplasia benign prostatic hyperplasia n. Abbr. BPH A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. . Originally discovered by Kissei Pharmaceutical Co., Ltd., it was developed by Daiichi Sankyo and Kissei Pharmaceutical and is jointly marketed as Urief in Japan. KMD-3213 has shown efficacy in significantly improving urinary disturbance soon after dosage and is expected to contribute to improving the quality of life in patients. JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion